Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the state of the EU biosimilars market.
So I think what’s very important to notice is that biosimilars are used everywhere, in every country. And I think this is important; we’ve had 28 countries until now, and I think it's important to see they are used by every healthcare system.
The nuance in there is that they are used in a variable fashion. So between countries you see a massive difference, and within countries you also see massive differences between the different biosimilars available.